| Source publication date | |
|---|---|
| Reported on Testosterone Science | |
| Outlet type | Mainstream news |
| Population | Men |
| Source | ThePrint |
| URL | theprint.in/world/us-aims-for-a-high-t-military-pentagon-to-annually-screen-troops-aged-30-above-for-testosterone/2988119 (opens in a new tab) |
Specific Claim Evaluated
Testosterone levels generally decline with age, but medical guidelines do not ordinarily recommend testing every man after a particular age.
Primary Research Supporting or Contradicting the Claim
In a population-based survey, 24% of men aged 30 to 79 years had total testosterone below 300 ng/dL, while the crude prevalence of symptomatic androgen deficiency was 5.6% (Araujo et al., 2007). Guidelines restrict diagnosis to men with symptoms and confirmed low levels (Bhasin et al., 2018).
Corrected Evidence-Based Interpretation
Accurate.
Rationale for Grade
The article supplies the guideline context that is missing from some other coverage of the same announcement. Its statements on age-related decline and testing practice are consistent with population and guideline data. It reports official statements with attribution.
References
- Araujo AB, Esche GR, Kupelian V, O'Donnell AB, Travison TG, Williams RE, Clark RV, McKinlay JB. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab. 2007;92(11):4241-4247. PMID
Supporting excerpt: "Crude prevalence of symptomatic androgen deficiency was 5.6%" - Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, Snyder PJ, Swerdloff RS, Wu FC, Yialamas MA. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. PMID
Supporting excerpt: "We recommend making a diagnosis of hypogonadism only in men with symptoms and signs"